Expression Of RRM2 In The Epithelian Ovarian Cancer And Its Relation To Tumor Vascularization

Objective:To investigate the role of RRM2 in the Epithelian Ovarian Cancer and its relation to tumor vascularization.Methods:The mRNA and protein levels of RRM2 and CD105 in 98 ovarian specimens(including 15 normal,15 benign,6 borderline and 62 malignant) were detected with reverse transcription-polymerase chain reaction(RT-PCR)and immunohistochemistry. Microvessel density (MVD) was counted by endothelial cells immunostained with anti-CD105 monoclonal antibody.The relationship between the expressions of two genes was analyzed. The survival time after operation was followed up.Results:(1) The mRNA levels (1.586±0.650,1.870±0.618)and protein positive rates(66.67%,69.35%) of RRM2 in borderline ovarian neoplasms and ovarian cancers wereand were both higher than that in normal group and benign group(0.771±0.495,0.952±0.601and 0,26.67%)(P<0.05); the mRNA levels(2.190±0.512, 2.735±0.636) and MVD(23.15±4.38,25.27±6.91) of CD 105 in borderline ovarian neoplasms and ovarian cancers were both higher than that in normal group and benign group(0.686±0.637,0.763±0.547 and 3.40±1.78,12.15±2.29)(P<0.05).(2) The mRNA levels and positive rates of RRM2 were higher in clinical stageⅢ～Ⅳthan that in stageⅠ～Ⅱ(t=-2.370,χ2=5.937,P<0.05); the mRNA levels and MVD of CD105 were associated with FIGO stage, grades of cytology differentiation, and the presence of lymph node metastasis(P<0.05).(3)Expression of RRM2mRNA was positively correlated with CD105mRNA expression in ovarian cancer tissues (r=0.713, P<0.05). (4) Kaplan-Meier method showed that patients survived shorter when ovarian cancer tissues showed higher positive rates of RRM2 (P<0.05);COX proportional risk model analysis indicated that the risk of mortality with high level of RRM2mRNA is 2.378 times as large as that with low.Conclusion:(1) RRM2 maybe another new tumor marker for the diagnosis and judging prognosis in epithelical ovarian cancer. (2) RRM2 may be associated with the angiogenesis of epithelian ovarian cancer. (3) RRM2 may be another new tumor marker for predicting the prognosis in epithelical ovarian cancer.